Sign in

US clears Moderna’s Covid-19 vaccine for emergency use

Jointly developed by Moderna, a Massachusetts-based pharma company, and the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine has been authorised for use on people aged 18 years and older

Updated on: Dec 19, 2020, 09:53:32 IST
Hindustan Times, Washington, DC | By
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

The fight against Covid-19 received a major shot in the arm on Friday as the US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) to a second vaccine against the deadly coronavirus disease.

A file photo taken on November 18, 2020 shows a bottle reading Vaccine Covid-19 next to the Moderna biotech company logo. (AFP/ FILE)
A file photo taken on November 18, 2020 shows a bottle reading Vaccine Covid-19 next to the Moderna biotech company logo. (AFP/ FILE)

Jointly developed by Moderna, a Massachusetts-based pharma company, and the National Institute of Allergy and Infectious Diseases (NIAID), the Covid-19 vaccine has been authorised for use on people aged 18 years and older, and has joined Pfizer-BioNTech’s vaccine, already being administered since Monday, on the frontlines of the battle against the virus.

Moderna’s vaccine is similar to the one created jointly by Pfizer and BioNTech in many ways. They were both developed using the same cutting-edge mRNA technology and need to be administered in two doses, primary and booster.

But they are also different: the Moderna vaccine is more convenient to store and transport; common refrigerators would serve the purpose instead of the super-coolers needed for the Pfizer-BioNTech vials. Also, the interval between the two doses is longer by a week.

“There is much we still do not know about Sars-CoV-2 and Covid-19,” said Dr. Anthony Fauci, the most respected voice in the US on the pandemic and the head of the NIAID. “However, we do know that this vaccine is safe and can prevent symptomatic Covid-19 and severe disease.”

Moderna expects to supply between 100 million and 125 million doses globally in the first quarter of 2021, with 85-100 million of those doses available in the US.

The US food and drug regulator granted EUA to Moderna’s Covid-19 vaccine a day after an advisory board of outside experts had cleared it overwhelmingly. Its distribution, however, will depend on one more clearance, from the US Centers of Disease Control and Prevention (CDC), which is expected to follow shortly.

The United States is witnessing a continuing spike in Covid-19 cases. More than 233,000 new infections were reported in the last 24 hours and 3,270 fatalities. Dr. Fauci and other experts have warned of a grim winter with far more cases likely. More than 17 million Covid-19 cases have been reported in the US so far with at least 313,246 deaths.

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More